Compare · CNSY vs RMD
CNSY vs RMD
Side-by-side comparison of Cerenome Inc. (CNSY) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSY and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.60B, about 5742.4x CNSY ($5.9M).
- Over the past year, CNSY is down 94.3% and RMD is down 5.2% - RMD leads by 89.1 points.
- RMD has been more active in the news (10 items in the past 4 weeks vs 4 for CNSY).
- RMD has more recent analyst coverage (25 ratings vs 0 for CNSY).
- Company
- Cerenome Inc.
- ResMed Inc.
- Price
- -
- -
- Market cap
- $5.9M
- $33.60B
- 1M return
- -56.01%
- +1.61%
- 1Y return
- -94.27%
- -5.18%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 10
- Recent ratings
- 0
- 25
Cerenome Inc.
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest CNSY
- Chief Business Officer Andrews Ronald Asbury was granted 92,858 stock options (SEC Form 4)
- Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
- Cerenome Appoints Director Ron Andrews as Chief Business Officer
- Cerenome Secures National In-Network Agreement with Aetna for CNSide®
Latest RMD
- Director De Witte Jan covered exercise/tax liability with 60 units of ResMed Common Stock, decreasing direct ownership by 1% to 4,201 units (SEC Form 4) (for tax liability)
- Director Gill Harjit covered exercise/tax liability with 36 units of ResMed Common Stock, decreasing direct ownership by 0.33% to 10,904 units (SEC Form 4) (withholding tax)
- Global General Counsel Rider Michael J covered exercise/tax liability with 1,944 units of ResMed Common Stock, decreasing direct ownership by 16% to 10,417 units (SEC Form 4) (withholding obligation)
- Chairman and CEO Farrell Michael J. exercised 4,993 units of ResMed Common Stock at a strike of $146.34 and sold $1,175,089 worth of ResMed Common Stock (4,993 units at $235.35) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed downgraded by Canaccord Genuity
- SEC Form 10-Q filed by ResMed Inc.
- SEC Form 8-K filed by ResMed Inc.
- Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2027
- Global General Counsel Rider Michael J sold $102,000 worth of ResMed Common Stock (400 units at $255.00) as part of a pre-agreed trading plan (SEC Form 4)
- Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.